OneChain Immunotherapeutics (OCI), a clinical-stage biotechnology company focused on the development of CAR T therapies for the treatment of oncologic diseases, has named Stefanos Theoharis, Ph.D., as the company’s new Chief Executive Officer.   He succeeds Jorge Alemany, Ph.D., who has served as CEO since the creation of the company in June 2020 and will now retire. About Stefanos Theoharis Theoharis has more than twenty years of experience in the field of cell and gene therapy, bu...